By: Benzinga
December 10, 2012 at 11:07 AM EST
UPDATE: Stifel Nicolaus Cuts PT to $40 on Endo Health Solutions on Competitive Headwinds
Stifel Nicolaus reiterated its Buy rating on Endo Health Solutions (NASDAQ: ENDP ) but reduced its price target from $44 to $40. Stifel Nicolaus noted, "Facing generic entry from Impax on its older, non tamper-resistant formulation (non-TRF) of Opana ER on 1/1/13, Endo had hoped to force a decision
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here